Abstract
The mammalian target of rapamycin (mTOR) is frequently activated in epithelial ovarian cancer, and is regarded as an attractive therapeutic target for therapy. Preclinical investigations using rapamycin and its analogs have demonstrated significant growthinhibitory effects on the growth of ovarian cancer both in the setting of monotherapy and in combination with cytotoxic agents. Based on promising preclinical data, mTOR inhibitors are currently being evaluated in several phase I/II trials in patients with ovarian cancer. In an effort to overcome resistance to rapamycin and its analogs, the novel ATP-competitive mTOR inhibitors have recently been developed. In this report, we review the scientific rationale and evidence for the potential clinical benefits provided by mTOR inhibitor therapy for patients with epithelial ovarian cancer.
Keywords: mTOR, mTORC1, mTORC2, AKT, ovarian cancer, rapamycin, rapalogs, everolimus, temsirolimus, ATP-competitive mTOR inhibitors
Current Medicinal Chemistry
Title: Targeting mTOR Signaling Pathway in Ovarian Cancer
Volume: 18 Issue: 19
Author(s): S. Mabuchi, T. Hisamatsu and T. Kimura
Affiliation:
Keywords: mTOR, mTORC1, mTORC2, AKT, ovarian cancer, rapamycin, rapalogs, everolimus, temsirolimus, ATP-competitive mTOR inhibitors
Abstract: The mammalian target of rapamycin (mTOR) is frequently activated in epithelial ovarian cancer, and is regarded as an attractive therapeutic target for therapy. Preclinical investigations using rapamycin and its analogs have demonstrated significant growthinhibitory effects on the growth of ovarian cancer both in the setting of monotherapy and in combination with cytotoxic agents. Based on promising preclinical data, mTOR inhibitors are currently being evaluated in several phase I/II trials in patients with ovarian cancer. In an effort to overcome resistance to rapamycin and its analogs, the novel ATP-competitive mTOR inhibitors have recently been developed. In this report, we review the scientific rationale and evidence for the potential clinical benefits provided by mTOR inhibitor therapy for patients with epithelial ovarian cancer.
Export Options
About this article
Cite this article as:
Mabuchi S., Hisamatsu T. and Kimura T., Targeting mTOR Signaling Pathway in Ovarian Cancer, Current Medicinal Chemistry 2011; 18 (19) . https://dx.doi.org/10.2174/092986711796150450
DOI https://dx.doi.org/10.2174/092986711796150450 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serotonin and Cancer: What Is the Link?
Current Molecular Medicine Synthesis and In Vitro Antitumor Effect of New Vindoline-steroid Hybrids
Current Organic Chemistry Targeting Telomerase for Cancer Therapy
Current Cancer Therapy Reviews The Typical Metabolic Modifiers Conferring Improvement in Cancer Resistance
Current Medicinal Chemistry Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections
Current Topics in Medicinal Chemistry Paclitaxel Formulations: Challenges and Novel Delivery Options
Current Drug Delivery Targeted Therapy of Ovarian Cancer with Angiogenesis Inhibitors
Current Drug Targets Imaging Requirements for Personalized Medicine: The Oncologists Point of View
Current Pharmaceutical Design Pyrazolopyrimidine Derivatives as Antineoplastic Agents: with a Special Focus on Thyroid Cancer
Mini-Reviews in Medicinal Chemistry Anticancer Potential of Mefenamic Acid Derivatives with Platelet-Derived Growth Factor Inhibitory Property
Anti-Cancer Agents in Medicinal Chemistry The Effects of Mesenchymal Stem Cells in Craniofacial Tissue Engineering
Current Stem Cell Research & Therapy Imaging of Integrins as Biomarkers for Tumor Angiogenesis
Current Pharmaceutical Design BRCA1-Associated Triple-Negative Breast Cancer and Potential Treatment for Ruthenium-Based Compounds
Current Cancer Drug Targets Scheduling of Taxanes: A Review
Current Clinical Pharmacology Recent Progress in the Development of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents A Review on Novel Breast Cancer Therapies: Photodynamic Therapy and Plant Derived Agent Induced Cell Death Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Protein Kinase C as a Drug Target Implications for Drug or Diet Prevention and Treatment of Cancer
Current Drug Targets Application of Proteomics to the Discovery of Cancer Biomarkers
Current Cancer Therapy Reviews Silencing of Disease-related Genes by Small Interfering RNAs
Current Molecular Medicine